We transform discoveries in the gut–brain axis, advanced microbiology and nanotechnology into clinically validated, scalable platforms for neurological health, precision nutrition, dermocosmetics and human performance.
Our multidisciplinary model connects microbiology, neuroscience, integrative medicine, biotechnology, nanotechnology and clinical operations to convert complex research into protected, reproducible and commercially viable healthcare solutions.
Each platform is designed to move from discovery to validation and industrial scale without losing scientific rigor.
Functional strain isolation, genomic identification, microbiological characterization, scalable fermentation and advanced microencapsulation for gut–brain axis applications.
Bio-intelligent delivery systems engineered to improve stability, protection, absorption and targeted release of microorganisms and bioactive compounds.
High-performance formulations combining biotechnology and multi-phase release for metabolic, gastrointestinal, cognitive and physical performance applications.
Natural bioactives, biotechnology and intelligent delivery for precision skincare, melasma, lifting, lipedema and inside-out beauty programs.
Our CRO and R&D infrastructure operate under Good Clinical Practice principles, integrating clinical validation, regulatory strategy, intellectual property and go-to-market execution.
Through our CRO structure, we mobilize a multidisciplinary network of experienced researchers across protocol development, clinical operations, data quality, safety, regulatory documentation and scientific publication.
A controlled development sequence ensures identity, purity, functionality, stability and scalability.
Natural and controlled biological sources.
Phenotypic and metabolic screening.
Sequencing and international deposit.
Viability and contaminant control.
Adherence, metabolites and bioactivity.
Pilot and industrial fermentation.
Reproducible quality specifications.
Accelerated and real-time stability, strain viability, microencapsulation integrity and targeted release.
Pathogen absence, total counts, endotoxin testing, molecular strain identification and qPCR.
Residual moisture, pH, solubility, dispersion, particle size, uniformity and thermal behavior.
Simulated GI transit, epithelial adhesion, post-release metabolism, cytotoxicity, genotoxicity and sensitization.
Research programs are the visible layer of deeper proprietary technology platforms.
ProbMax is a proprietary microbiome-based biotechnology developed by NeuroProb Biotech and investigated through a randomized controlled clinical research program.
Clinical findings from the research program were reported in BMC Pediatrics, a Springer Nature journal, in March 2026.
Additional findings were reported in Life (MDPI) in May 2026. The statements on this page refer to observations obtained under the specific conditions of the clinical research.
ProbMax is not currently in commercial production and is not available for sale or distribution. It is undergoing internal scientific, technical and regulatory evaluation, including assessment of the research findings and potential regulatory classification and registration pathways.
The scientific statements presented here are based on findings obtained in a randomized controlled trial (RCT) and related clinical research. They should not be interpreted as guaranteed clinical benefits, medical advice, regulatory approval, or authorization for therapeutic use.
ProbMax is not presented as a treatment, cure or preventive intervention for autism spectrum disorder or any other medical condition. Any future commercialization will depend on completion of applicable development, manufacturing, regulatory and compliance requirements.
Biotech NeuroProb is a U.S.-based biotechnology company focused on research, development, clinical validation and commercialization of advanced health technologies. Our planned Arlington, Texas facility will connect scientific excellence with scalable industrial execution and strategic partnerships.
Already operating in the United States: Biotech NeuroProb maintains an active business office in Miami, Florida, supporting corporate operations, strategic development and international partnerships.
Scientific collaborations, licensing, co-development, clinical validation and strategic investment.
contact@biotechneuroprob.com ↗